GI
2024 ESMO Annual Meeting Insights Hub
ESMO 2024 Insights: IMHOTEP Trial - Neo-Adjuvant IO for dMMR/MSI CRC
FEATURING
Olivier Dubreuil
- 40 views
- November 25, 2024
2024 ESMO Annual Meeting Insights Hub
ESMO 2024 Insights: Efficacy of 177Lu-DOTA-TATE in GEP-NETs - Multivariate Analysis of NETTER-2 Study
FEATURING
Diego Ferone
- 40 views
- November 13, 2024
2024 ESMO Annual Meeting Insights Hub
ESMO 2024 Summary: Optimal Sequencing of Therapeutic Strategies in Immunogenic mCRC
FEATURING
Thierry André
- 54 views
- November 5, 2024
2024 ESMO Annual Meeting Insights Hub
ESMO 2024 Summary: Sequencing CRC Targeted Therapies Based on Biomarkers and Biology
FEATURING
Lukas Weiss
- 67 views
- November 4, 2024
2024 ESMO Annual Meeting Insights Hub
ESMO 2024 Summary: Late-Line Therapy in mCRC - How to Choose
FEATURING
Howard Hochster
- 500 views
- September 23, 2024
- 5
2024 ESMO Annual Meeting Insights Hub
ESMO 2024 Summary: Neoadjuvant Colon Cancer Treatment - Recent Clinical and Translational Advances
FEATURING
Julien Taieb
- 355 views
- October 6, 2024
- 1
2024 ESMO Annual Meeting Insights Hub
ESMO 2024 Summary: Selecting 1L Therapy and Sequencing After Immunotherapy in Unresectable HCC
FEATURING
Lorenza Rimassa
- 410 views
- September 20, 2024
- 5
2024 ESMO Annual Meeting Insights Hub
ESMO 2024 Summary: Highlights in HCC
FEATURING
Richard Kim,
Tiago Biachi
- 227 views
- October 21, 2024
- 3
2024 ESMO Annual Meeting Insights Hub
ESMO 2024 Summary: Highlights in CRC and Impacts on Practice
FEATURING
Richard Kim,
Tiago Biachi
- 241 views
- October 21, 2024
- 5
2024 ESMO Annual Meeting Insights Hub
ESMO 2024 Summary: Latest Advances in Targeted Therapies for Pancreatic Cancer
FEATURING
Davide Melisi
- 254 views
- October 17, 2024
- 3
2024 ESMO Annual Meeting Insights Hub
ESMO 2024 Summary: Updates in Pancreatic Cancer and Impacts on Practice
FEATURING
Hani Babiker
- 339 views
- October 14, 2024
- 5
2024 ESMO Annual Meeting Insights Hub
ESMO 2024 Summary: Updates in HCC and Impacts on Practice
FEATURING
Hani Babiker
- 175 views
- October 14, 2024
- 1
2024 ESMO Annual Meeting Insights Hub
ESMO 2024 Summary: Liquid Biopsies in GI Cancers - Learnings From Colorectal Cancer
FEATURING
Naureen Starling
- 192 views
- October 7, 2024
2024 ESMO Annual Meeting Insights Hub
ESMO 2024 Summary: Optimizing Curative Opportunities in Early HCC
FEATURING
Stephen L. Chan
- 112 views
- October 2, 2024
- 2
2024 ESMO Annual Meeting Insights Hub
ESMO 2024 Summary: The Emerging Global Epidemic of Early-Onset Cancer - Nature vs. Nurture
FEATURING
Shuji Ogino
- 351 views
- October 1, 2024
- 2
2024 ESMO Annual Meeting Insights Hub
ESMO 2024 Summary: IDH Mutated AML - Diagnostic and Treatment Paradigm
FEATURING
Teresa Macarulla Mercade
- 55 views
- September 30, 2024
2024 ESMO Annual Meeting Insights Hub
ESMO 2024 Summary: Treatment Strategies and Sequencing in Carcinoid Syndrome
FEATURING
Rachel Riechelmann
- 108 views
- September 24, 2024
- 4
ecancer
ESMO 2024 Insights: NO-CUT Trial - Total Neoadjuvant Treatment Without Surgery for Locally Advanced Rectal Cancer
FEATURING
Alessio Amatu
- 188 views
- October 14, 2024
- 1
ecancer
ESMO 2024 Insights: ROME Basket Trial - Targeting Actionable Mutations vs. SoC in Pts With Advanced Solid Tumors
FEATURING
Andrea Botticelli
- 15 views
- October 22, 2024
2024 ESMO Annual Meeting Insights Hub
ESMO 2024 Insights: CheckMate 9DW Expanded Analysis - Nivo + Ipi vs. Len or Sorafenib in 1L Unresectable HCC
FEATURING
Hatim Karachiwala
- 137 views
- October 21, 2024
- 2
2024 ESMO Annual Meeting Insights Hub
ESMO 2024 Insights: Machine Learning-Based Prediction of Lymph Node Metastasis in Early Gastric Cancer
FEATURING
Weiyao Li
- 15 views
- October 21, 2024
2024 ESMO Annual Meeting Insights Hub
ESMO 2024 Insights: The Value of Immune Checkpoint Blockade in MSS/pMMR mCRC
FEATURING
Benjamin Geisler
- 133 views
- October 8, 2024
2024 ESMO Annual Meeting Insights Hub
ESMO 2024 Insights: EPOC2001 Study - Lenvatinib + Pembro + FLOT in Neoadjuvant/Adjuvant Treatment for Gastric and GEJ Adenocarcinoma
FEATURING
Akihito Kawazoe
- 160 views
- October 3, 2024
2024 ESMO Annual Meeting Insights Hub
ESMO 2024 Insights: DESTINY-Gastric03 - T-DXd Monotherapy and Combinations in Pts With Adv/Metastatic HER2+ Esophageal, Gastric, or GEJ Adenocarcinoma
FEATURING
Yelena Janjigian
- 139 views
- October 2, 2024
- 2
2024 ESMO Annual Meeting Insights Hub
ESMO 2024 Insights: HIMALAYA - 5-Year OS of Tremelimumab + Durvalumab in Unresectable HCC
FEATURING
Lorenza Rimassa
- 176 views
- September 20, 2024
2024 ESMO Annual Meeting Insights Hub
ESMO 2024 Insights: Nal-IRI/LV5-FU vs. Paclitaxel as 2L Therapy in Metastatic Esophageal SCC - OESIRI-PRODIGE 62 Study
FEATURING
David Tougeron
- 63 views
- September 27, 2024
2024 ESMO Annual Meeting Insights Hub
ESMO 2024 Insights: Fruquintinib in Refractory mCRC - Subgroup Analysis of the FRESCO-2 Trial
FEATURING
Rocio Garcia-Carbonero
- 61 views
- October 1, 2024
2024 ESMO Annual Meeting Insights Hub
ESMO 2024 Insights: POD1UM-303/InterAACT 2 - Retifanlimab + C-P in Untreated Inoperable or Metastatic Anal Squamous Cell Carcinoma
FEATURING
Sheela Rao
- 71 views
- September 27, 2024
- 1
2024 ESMO Annual Meeting Insights Hub
ESMO 2024 Insights: Pembro + CAPOX + Bevacizumab in MSS mCRC With High Immune Infiltrate - FFCD 1703 POCHI Trial
FEATURING
David Tougeron
- 84 views
- September 27, 2024
- 1
2024 ESMO Annual Meeting Insights Hub
ESMO 2024 Insights: TACE ± Lenvatinib + Pembro for Int-Stage HCC - Ph3 LEAP-012 Study
FEATURING
Josep Llovet
- 211 views
- September 23, 2024
- 3